BIORESTORATIVE THERAPIES INC. - COMMON STOCK

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

12 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

08 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces $2.1 Million Registered Direct Offering

11 Jul 2023 08:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes

27 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

16 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease

12 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare Conference

01 Jun 2023 09:15:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing

31 May 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

15 May 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company’s Phase 2 Clinical Trial

08 May 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies, Inc. to participate at the EF Hutton Global Conference May 10-11 in New York City

04 May 2023 07:00:01 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100

24 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100

13 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023

07 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

02 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program

08 Feb 2023 09:00:01 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication

06 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease

05 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022

29 Nov 2022 11:20:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

16 Nov 2022 08:56:00 By Nasdaq GlobeNewswire